Biorelate

Medical data curation

Biorelate

Sector

Application Software

Location

Manchester

Deal type

Growth Capital

Investment size

£2.6m

Investment date(s)

2022

Website

biorelate.com

"Drug discovery is so exciting right now, as there are just so many incredible companies working on remarkable new therapeutics. Our mission at Biorelate is to capture this untapped data and help them make sense of it. With this improved understanding we are empowering these companies to make better decisions and speed up the drug discovery process."

Dan Jamieson, founder and CEO of Biorelate

The business

  • Biorelate curates dark biomedical knowledge to empower drug discovery with its proprietary AI platform, Galactic AI™
  • Galactic AI’s technology combines natural language processing and machine learning to capture valuable biomedical data that pharmaceutical and life sciences organisations can utilise to improve decision making
  • Impressive customer base, including some of the biggest names in biopharma globally

The strategy

  • Scale up the commercial and technical teams
  • Expansion into the US to tap into the industry’s largest market
  • Continued investment into product development

Related news

YFM invests in deep tech AI company Biorelate
YFM invests in deep tech AI company Biorelate

29 November 2022

Back to top